Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature
- PMID: 18176844
- DOI: 10.1007/s11102-007-0080-4
Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature
Abstract
Corticotroph pituitary carcinomas are tumors, defined by the presence of distant metastases that determine their poor prognosis. The diagnosis and therapy of malignant corticotroph adenomas remains a clinical challenge. The molecular mechanisms of malignant transformation of pituitary adenomas are unclear, although they are believed to arise in an adenoma-to-carcinoma sequence. We describe two cases of malignant Cushing's disease with metastases in liver and bone, respectively. The primary pituitary tumors were treated by a combination of radiotherapy and transsphenoidal surgery, but recurred several times in both patients. The time interval between the diagnosis of Cushing's disease and the discovery of metastases was 32 and 17 years, respectively. In the first case the patient died within 6 months after diagnosis of metastasis, whereas the second patient is alive at a follow-up of 2 years after the discovery of the metastasis. Furthermore, we reviewed all available cases of corticotroph pituitary carcinomas reported in the literature and analyzed their clinical features and therapeutical management. In conclusion, frequent relapses of Cushing's disease, aggressive growth of macroadenoma, Nelson's syndrome after adrenalectomy or persistently high ACTH levels should prompt the clinician to consider the possibility of pituitary corticotroph carcinomas.
Similar articles
-
Pituitary corticotroph hyperplasia preceding adenoma in a patient with Nelson's syndrome.Clin Neuropathol. 2006 Mar-Apr;25(2):74-80. Clin Neuropathol. 2006. PMID: 16550740
-
Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome.J Clin Endocrinol Metab. 2007 Jan;92(1):172-9. doi: 10.1210/jc.2006-1328. Epub 2006 Oct 24. J Clin Endocrinol Metab. 2007. PMID: 17062771
-
Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.Neurosurg Focus. 2015 Feb;38(2):E12. doi: 10.3171/2014.10.FOCUS14705. Neurosurg Focus. 2015. PMID: 25639314
-
The role of somatostatin analogs in Cushing's disease.Pituitary. 2004;7(4):257-64. doi: 10.1007/s11102-005-1404-x. Pituitary. 2004. PMID: 16132202 Review.
-
Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].Endocr J. 2014;61(10):941-8. doi: 10.1507/endocrj.ej14-0120. Epub 2014 Jun 29. Endocr J. 2014. PMID: 24974880 Review.
Cited by
-
Temozolomide therapy: Focus on patients with pituitary carcinoma.J Neurosci Rural Pract. 2016 Jul-Sep;7(3):335-6. doi: 10.4103/0976-3147.181478. J Neurosci Rural Pract. 2016. PMID: 27365946 Free PMC article. No abstract available.
-
Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: case report.J Spinal Cord Med. 2012 Mar;35(2):118-21. doi: 10.1179/2045772311Y.0000000055. Epub 2012 Feb 8. J Spinal Cord Med. 2012. PMID: 22333938 Free PMC article.
-
Invasive adenoma and pituitary carcinoma: a SEER database analysis.Neurosurg Rev. 2014 Apr;37(2):279-85; discussion 285-6. doi: 10.1007/s10143-014-0525-y. Epub 2014 Feb 14. Neurosurg Rev. 2014. PMID: 24526366 Free PMC article.
-
Molecular basis of pharmacological therapy in Cushing's disease.Endocrine. 2014 Jun;46(2):181-98. doi: 10.1007/s12020-013-0098-5. Epub 2013 Nov 23. Endocrine. 2014. PMID: 24272603 Review.
-
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.Pituitary. 2012 Sep;15(3):276-87. doi: 10.1007/s11102-011-0363-7. Pituitary. 2012. PMID: 22076588 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources